Who are Ticagrelor followed with Morphine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ticagrelor-followed-with-morphine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ticagrelor followed with Morphine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ticagrelor followed with Morphine (Ticagrelor followed with Morphine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 inhibitor (ticagrelor) + opioid analgesic (morphine). Area: Cardiovascular.

marketed P2Y12 inhibitor (ticagrelor) + opioid analgesic (morphine) P2Y12 receptor (ticagrelor); mu-opioid receptor (morphine) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ticagrelor followed with Morphine (Ticagrelor followed with Morphine) — Collegium Medicum w Bydgoszczy. Ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, while morphine provides opioid analgesia; together they are used in acute coronary syndrome to prevent thrombotic events and manage pain.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ticagrelor followed with Morphine TARGET	Ticagrelor followed with Morphine	Collegium Medicum w Bydgoszczy	marketed	P2Y12 inhibitor (ticagrelor) + opioid analgesic (morphine)	P2Y12 receptor (ticagrelor); mu-opioid receptor (morphine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 inhibitor (ticagrelor) + opioid analgesic (morphine) class)

Collegium Medicum w Bydgoszczy · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ticagrelor followed with Morphine — Competitive Intelligence Brief. https://druglandscape.com/ci/ticagrelor-followed-with-morphine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab